2023年4月4日

分享這篇文章分享這篇文章提供的新聞同行評議的雜誌,疼痛和治療發表一項新的研究集中在評估的有效性BioWave®非侵入性周圍神經刺激治療慢性疼痛。使用後的46%減少疼痛BioWave兩周。證實了一項新的研究發表在疼痛和治療。87.6%的患者報告的改善使用BioWave兩周後的生活質量。證實了一項新的研究發表在疼痛和治療。42%的患者報告藥物的使用是減少或消除在使用BioWave兩周。證實了一項新的研究發表在疼痛和治療。3.47分——平均減少疼痛評分(清廉規模)使用BioWave後兩周。它證實了一項新的研究發表在疼痛和治療。一項新的研究證實的療效BioWave pain-blocking技術治療慢性疼痛和改善生活質量。本文證實了小之前的研究的好處BioWave®技術治療慢性疼痛。病人的人口規模(1511名患者)是在有史以來最大的人口規模進行非侵入性周圍神經刺激。這項研究觀察了使用BioWaveHOME®設備在慢性疼痛治療。 Patients experienced significant reduction in overall pain and medication needs in just two weeks of starting to use BioWave®. BioWave® is a patented smarter pain blocking technology that provides immediate, deep, long-lasting relief of severe pain. BioWave devices deliver therapeutic electrical signals through skin directly to pain nerves in deep tissue to prevent pain from reaching the brain relieving chronic, acute or post-operative pain. BioWave technology provides 8 hours of pain relief on average following a 30-minute treatment*. It is easy to use at home or on the go. The five main outcomes the study found were: overall pain reduction after using BioWave for two weeks was 46%. The average reduction in pain score was 3.47 points (0-10 scale), which is a significant reduction. An improvement in quality of life was reported in 87.6% of patients; 42% of patients reported they were able to eliminate or reduce their medication. Over 97% of patients wanted to continue the BioWave therapy. Most importantly the effect on functional lifestyle (mood, sleep, standing, sitting, etc.) was improved across the board. There were no adverse reactions or complications reported in the 1511 patient outcomes. "Although survey studies have inherent limitations such as duration and compliance biases with such an overwhelming benefit in every category, we believe that noninvasive neuromodulation therapy is a promising, safe, and cost-effective therapy," wrote the authors. "The recent study confirms the efficacy of our patented high frequency pain blocking technology for the treatment of severe chronic pain, and for improvement in function and qualities of life for patients," said Brad Siff, Founder & President of BioWave Corporation. "Our mission is to help people win their battle with severe pain so they can get back to their daily activities. BioWave is changing lives every day and it's extremely rewarding to be able to help these patients who suffer from pain. The published clinical paper demonstrates our dedication to providing proven, innovative efficacy for our customers," said Brad Siff. About BioWave Corp. BioWave is committed to delivering immediate, deep, and long-lasting relief of severe pain by offering innovative solutions to treat pain using the company's patented, high-frequency peripheral nerve stimulation technology . Products include BioWavePENS® , BioWavePRO® , BioWaveHOME® , BioWaveGO® RX, a portable unit, BioWaveGO an over-the-counter device, and BioWraps® , wearable compression electrode garments. BioWave® started in professional sports – the NY Football Giants were the company's first customer. Today BioWave has been used by over 140 NCAA teams and well over 100 PRO teams in the NFL, MLB, NBA, NHL, and MLS. BioWave technology and solutions are also widely used by many VA hospitals, active military bases, pain, and ortho clinics. BioWave devices are FDA-cleared, and clinically proven to deliver safe and effective treatment of pain without the need for prescription drugs. BioWave is available under Federal Supply Schedule contract number V797D-70205. More information about the company's products and solutions can be found at BioWave.com . Contacts